Bruce Silver Selected Research

Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)

2/2015

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruce Silver Research Topics

Disease

1	COVID-19 01/2022
1	Infections 01/2022
1	Pyruvate Kinase Deficiency of Red Cells 01/2019
1	Hemolysis 01/2019
1	Neoplasms (Cancer) 02/2015
1	Glioblastoma (Glioblastoma Multiforme) 02/2015

Drug/Important Bio-Agent (IBA)

1	AerosolsIBA 01/2022
1	mitapivatIBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 02/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015
1	CT-322IBA 02/2015
1	Fibronectins (Fibronectin)IBA 02/2015

Therapy/Procedure

1	Therapeutics 02/2015